To dissect the potential of vitamin C as a targeted therapy in T-ALL with loss of TET2, we obtained six T-ALL cell lines in which TET2 was expressed and unmethylated (SUP-T1, CCRF-CEM, JURKAT) or silent and methylated (LOUCY, TALL-1, DND-41) (Fig. 1 G and H and SI Appendix, Fig. S1B). This evidence concerns the gene TET2 and acute lymphoblastic leukemia.